CN105287478B - A kind of pharmaceutical composition treating gastritis - Google Patents
A kind of pharmaceutical composition treating gastritis Download PDFInfo
- Publication number
- CN105287478B CN105287478B CN201510755108.6A CN201510755108A CN105287478B CN 105287478 B CN105287478 B CN 105287478B CN 201510755108 A CN201510755108 A CN 201510755108A CN 105287478 B CN105287478 B CN 105287478B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- compound
- present
- gastritis
- treating gastritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of pharmaceutical composition treating gastritis, described pharmaceutical composition comprises the compound of effective dose and pharmaceutically acceptable carrier, and described compound has a having structure:
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of medicine treating gastritis
Compositions.
Background technology
Gastritis is digestion section office commonly encountered diseases, is also current common clinical, and gastritis majority is by imprisoning
Door pylori causes, but recent discovery performance, and other pathogenic bacterias are likely to cause stomach
Environment changes, and finds that eubacterium lentum ATCC 43055 is also one of pathogenic bacteria therein in the recent period.
Summary of the invention
It is an object of the invention to provide a kind of pharmaceutical composition treating gastritis.
In order to realize the purpose of the present invention, the present invention provides a kind of compound treating gastritis, should
Compound has a having structure:
The present invention also provides for a kind of pharmaceutical composition treating gastritis, and described pharmaceutical composition comprises
The compound of effective dose and pharmaceutically acceptable carrier, described compound has a having structure:
Preferably, described pharmaceutically acceptable carrier be diluent, disintegrating agent, binding agent,
Lubricant, stabilizer or corrigent.
Preferably, described diluent is sugar derivatives, starch derivatives or cellulose derivative.
Preferably, described diluent is lactose.
Preferably, described pharmaceutical composition is powder, microgranule, granule, capsule or sheet
Agent.
The present invention also provides for compound purposes in the medicine of preparation treatment gastritis, this compound
There is having structure:
Preferably, described infection is caused by eubacterium lentum ATCC 43055.
The present invention also provides for compound preparation vitro inhibition eubacterium lentum ATCC's 43055
Purposes in medicine, this compound has a having structure:
Term used herein " pharmaceutically acceptable " refers to not eliminate compound as herein described
Biologic activity or the material of character, such as carrier or diluent.This kind of material is applied to individual
Body is not resulted in undesirable biological action or not with harmful way and the compositions comprising it
In any component interact.
" pharmaceutically acceptable carrier " includes any and all of molten as the term is employed herein
Agent, disperse medium, coating material, surfactant, antioxidant, preservative are (the most anti-
Microbial inoculum, antifungal), isotonic agent, absorption delaying agent, salt, preservative, drug stabilizing agent,
Binding agent, excipient, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its group
Closing, this is well-known to those skilled in the art (for example, see Remington's
Pharmaceutical Sciences,18th Ed.Mack Printing
Company,1990,pp.1289-1329).In addition to the carrier incompatible with active component,
Treatment or pharmaceutical composition consider use any conventional carrier.
The compound of the present invention is notable for the pathogen effect causing gastrointestinal, can develop into and face
Pharmaceutical composition the newest on bed.
Detailed description of the invention
Below by way of the description of detailed description of the invention, the invention will be further described, but this is not
Being limitation of the present invention, those skilled in the art, according to the basic thought of the present invention, can do
Go out various amendment or improvement, but without departing from the basic thought of the present invention, all in the present invention
Within the scope of.
Experimental example the compounds of this invention is at the medicine of preparation vitro inhibition eubacterium lentum ATCC 43055
The research of the purposes in thing
Bacteriostatic test
Use following compounds, use filter paper enzyme classical in this area to carry out antibacterial examination
Test, wherein:
The structural formula of target compound is:
For examination strain eubacterium lentum ATCC 43055 purchased from north, the Shanghai promise limited public affairs of biotechnology
Department.
Culture fluid
Nutrient agar and nutrient broth, purchased from Chen Yu experimental facilities company limited of BeiJing ZhongKe.
Test method
Eubacterium lentum ATCC 43055 is inoculated in agar plate nutritional solution plane, inoculation
Time uniformly gather.
Weigh target compound 0.01 gram, add 15000 milliliters of sterilized water, ultrasonic 30 minutes,
Then the filtering with microporous membrane of 0.22 μm, obtains solution.Tweezer aseptic circular filter paper sheet, spray
Spill and state solution to complete wetting, be attached in the agar plate nutritional solution plane of inoculated bacteria.
Agar plate is placed in the incubator of 37 DEG C, incubation 4 hours.Measure the diameter of antibacterial ring.
Measure and average for 3 times.
1.4 result
The average diameter of the antibacterial ring of eubacterium lentum ATCC 43055 is 13.86mm, this table
Bright target compound has the effect of extremely strong vitro inhibition eubacterium lentum ATCC 43055.
Claims (1)
1. compound purposes in the medicine of preparation vitro inhibition eubacterium lentum ATCC 43055, it is characterised in that this compound has a having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510755108.6A CN105287478B (en) | 2015-11-09 | 2015-11-09 | A kind of pharmaceutical composition treating gastritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510755108.6A CN105287478B (en) | 2015-11-09 | 2015-11-09 | A kind of pharmaceutical composition treating gastritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105287478A CN105287478A (en) | 2016-02-03 |
| CN105287478B true CN105287478B (en) | 2016-09-21 |
Family
ID=55185772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510755108.6A Expired - Fee Related CN105287478B (en) | 2015-11-09 | 2015-11-09 | A kind of pharmaceutical composition treating gastritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105287478B (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3947594A (en) * | 1973-05-07 | 1976-03-30 | Gaf Corporation | 4-Halo-1-hydroxyanthraquinone containing fungicidal composition |
| CN1113844C (en) * | 2000-09-26 | 2003-07-09 | 上海市中药研究所 | Process for extracting and separating anthraquinone compound from Chinese herbal medicinal material |
-
2015
- 2015-11-09 CN CN201510755108.6A patent/CN105287478B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN105287478A (en) | 2016-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103919784A (en) | Application of A-ring trihydroxyl substituted pentacyclic triterpene compound to pharmacy | |
| CN105198903B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN104083364B (en) | A kind of pharmaceutical composition for the treatment of the infantile respiratory tract infection that enterobacter cloacae causes | |
| CN105287478B (en) | A kind of pharmaceutical composition treating gastritis | |
| CN105412076B (en) | Compound purposes in the medicine of preparation treatment infantile diarrhea | |
| CN105748478B (en) | A kind of medicine treating infantile diarrhea | |
| CN105232550B (en) | A kind of pharmaceutical composition treating chronic pelvic inflammatory disease | |
| CN105232542B (en) | A kind of pharmaceutical composition for the treatment of infantile pneumonia | |
| CN105232540A (en) | Drug combination for treating infection after burn | |
| CN105748477B (en) | A kind of medicine treating infantile enteritiss | |
| CN105348183A (en) | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom | |
| CN105294535A (en) | Pharmaceutical composition used for treating pelvic inflammation | |
| CN105395538B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN105622619A (en) | Medicine composition for treating periodontitis | |
| CN105061331A (en) | Pharmaceutical composition for eliminating phlegm for children | |
| CN105237542A (en) | Medicine composition for treating gynecological diseases | |
| CN105232504B (en) | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection repeatedly | |
| CN105218460A (en) | A kind of pharmaceutical composition for the treatment of enteritis | |
| CN105191948B (en) | A kind of control laboratory disinfectant | |
| CN106214685A (en) | A kind of pharmaceutical composition treating scald postoperative infection | |
| CN105125546A (en) | Medicine composition for treating postoperative wound infection | |
| CN105348270B (en) | A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp | |
| CN105560234A (en) | Medicine composition for treating oral and maxillofacial inflammation | |
| CN105777612A (en) | Medicine composition for treating children recurrent respiratory infection | |
| CN105796564A (en) | Medicine composition for preventing and treating infection of teeth and dental pulp |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xu Li Inventor after: Sun Xiangrong Inventor after: Guo Feifei Inventor after: Xu Ran Inventor after: Zhang Yanzhi Inventor before: Wei Fang |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160818 Address after: 266000 No. 308, Ningxia Road, Laoshan District, Shandong, Qingdao Applicant after: Qingdao University Address before: 071003 Hebei Province, Baoding City area Yonghua No. 19 North Street Applicant before: Wei Fang |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160921 Termination date: 20191109 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |